Par-4 was first identified through its down-regulation in therapy-resistant prostate cancer cells and has since been shown to be ubiquitously expressed, localized in the cytoplasm, the nucleus and extracellularly, and linked to a variety of cancers [2,3,4,5]. Here, PAWR is linked to cancer.